Oxford Capital and Finance Wales inject £3.5m into BioMonde

The investment will allow BioMonde to open a production plant in the US and to launch its patented BioBag product in the US.

Oxford Capital cited 10% annual growth forecasts for the LBT market as motivation for the deal, in addition to BioMonde's position on the European market. The GP stated that high levels of M&A activity in the wound care sector give BioMonde strong options for a future trade sale.

Oxford Capital recently led a $5m round for Dundee-based Outplay Entertainment, a developer of computer games for mobile operating systems. In April 2014, Finance Wales and Mercia Fund Management led a $1m series-A round for Thalia Design Automation.

Previous funding
Finance Wales has backed BioMonde since 2005, when it was called ZooBiotic. In 2010, the investment firm provided capital for ZooBiotic's acquisition of BioMonde, then a Germany-based company.

Company
Bridgend-based BioMonde is a wound care company that specialises in larval debridement therapy. It has a turnover of £5m and currently sells 35,000 treatments per year in Europe. It was recently granted approval from US authorities to sell BioBag in the US and plans to start sales in the country during the second half of 2014.

People
Colin Watts is a partner at Oxford Capital. Gareth Kempson is CEO of BioMonde. Gareth Price is portfolio executive at Finance Wales.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Expansion
• United Kingdom